EUVIMEDEUVIMED entdecken
Crossref

Blocking Deoxycytidine Kinase in Activated Lymphocytes Depletes Deoxycytidine Triphosphate Pools and Alters Cell Cycle Kinetics to Yield Less Disease in a Mouse Multiple Sclerosis Model

Jessica R Salas, K M Ryan, Alyssa O Trias, Bao Ying Chen, Miriam Guemes, Zoran Galic, Kenneth A Schultz, Peter M Clark iD

Immunology · 2025-02 · 174 (2) · 247-263

DOI: 10.1111/imm.13885 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunology, online erschienen am 22.12.2024. Verfasst von Jessica R Salas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Encephalomyelitis, Autoimmune, Experimental, Lymphocyte Activation, Deoxycytidine Kinase, Multiple Sclerosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 99 Literaturangaben. Gefördert von: NIAID NIH HHS, NINDS NIH HHS, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autoreactive, aberrantly activated lymphocytes that target myelin antigens in the central nervous system (CNS) are primary drivers of the autoimmune disease multiple sclerosis (MS). Proliferating cells including activated lymphocytes require deoxyribonucleoside triphosphates (dNTPs) for DNA replication. dNTPs can be synthesised via the de novo pathway from precursors such as glucose and amino acids or the deoxyribonucleoside salvage pathway from extracellular deoxyribonucleosides. Deoxycytidine kinase (dCK) is the rate‐limiting enzyme in the salvage pathway. In prior work, we showed that targeting dCK with the small molecule inhibitor TRE‐515 limits clinical symptoms in two myelin oligodendrocyte glycoprotein (MOG)‐induced experimental autoimmune encephalomyelitis (EAE) mouse models of MS and decreases the levels of activated CD4 T and B lymphocytes in vivo. However, whether targeting dCK limits disease in additional EAE models and how targeting dCK directly impacts activated and proliferating CD4 T and B cells has yet to be determined. Here, we show that dCK is activated in the lymph nodes and spleen in an EAE model induced by amino acids 139–151 of the proteolipid protein (PLP 139‐151 ) that is driven by CD4 T and B cells and is characterised by acute disease followed by disease remission. Treating this model with TRE‐515 limits clinical symptoms and decreases the levels of activated CD4 T and B cells. In culture, CD4 T and B cells induce deoxyribonucleoside salvage following activation, and TRE‐515 directly blocks CD4 T and B cell activation‐induced proliferation and activation marker expression. TRE‐515 decreases deoxycytidine triphosphate (dCTP) and deoxythymidine triphosphate (dTTP) pools and increases the length of time cells spend in S phase of the cell cycle without inducing a replication stress response in B cells. Our results suggest that dCK activity is required to supply needed dNTPs and to enable rapid cell division following lymphocyte activation against autoantigens in EAE mouse models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Encephalomyelitis, Autoimmune, ExperimentalLymphocyte ActivationDeoxycytidine KinaseMultiple SclerosisB-LymphocytesAnimalsMiceMice, Inbred C57BLCell CycleDisease Models, AnimalFemaleCD4-Positive T-LymphocytesCell ProliferationMyelin-Oligodendrocyte Glycoprotein

Stichwörter der Autor:innen

autoimmunitycell proliferationimaging

Substanzen

Deoxycytidine KinaseMyelin-Oligodendrocyte Glycoprotein

Autor:innen und Institutionen

  • Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California, USA.
  • Crump Institute for Molecular Imaging, UCLA, Los Angeles, California, USA.
  • Department of Medicine, UCLA, Los Angeles, California, USA.
  • Trethera Corporation, Sherman Oaks, California, USA.

ORCID-Profile: Peter M Clark

Förderung

  • NIAID NIH HHS
  • NINDS NIH HHS
  • Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles
  • NEI NIH HHS
  • UCLA Eugene Cota Robles Fellowship
  • Jonsson Comprehensive Cancer Center
  • UCLA Chancellor's Office
  • NIH HHS

Zitieren

APA

Salas, J. R., Ryan, K. M., Trias, A. O., Chen, B. Y., Guemes, M., Galic, Z., Schultz, K. A., & Clark, P. M. (2025). Blocking Deoxycytidine Kinase in Activated Lymphocytes Depletes Deoxycytidine Triphosphate Pools and Alters Cell Cycle Kinetics to Yield Less Disease in a Mouse Multiple Sclerosis Model. Immunology, 174(2), 247-263. https://doi.org/10.1111/imm.13885

Vancouver

Salas JR, Ryan KM, Trias AO, Chen BY, Guemes M, Galic Z, et al. Blocking Deoxycytidine Kinase in Activated Lymphocytes Depletes Deoxycytidine Triphosphate Pools and Alters Cell Cycle Kinetics to Yield Less Disease in a Mouse Multiple Sclerosis Model. Immunology. 2025;174(2):247-263. doi:10.1111/imm.13885

BibTeX
@article{Salas2025,
  author = {Salas, Jessica R and Ryan, K M and Trias, Alyssa O and Chen, Bao Ying and Guemes, Miriam and Galic, Zoran and Schultz, Kenneth A and Clark, Peter M},
  title = {Blocking Deoxycytidine Kinase in Activated Lymphocytes Depletes Deoxycytidine Triphosphate Pools and Alters Cell Cycle Kinetics to Yield Less Disease in a Mouse Multiple Sclerosis Model},
  journal = {Immunology},
  year = {2025},
  volume = {174},
  number = {2},
  pages = {247--263},
  doi = {10.1111/imm.13885}
}
Kostenlos starten →